Pinealon: benefits, evidence and legal status

Pinealon is a synthetic three-amino-acid peptide (Glu-Asp-Arg, or EDR) from Vladimir Khavinson’s bioregulator group in St. Petersburg, studied mainly in cells and rodents for brain protection; its strongest evidence is small uncontrolled human reports.

Its most promising result comes from rats: when pregnant rats with high homocysteine received pinealon, the share of dying cerebellar neurons in their offspring under oxidative stress fell from 17.7% to 7.0%, and the pups learned a water maze faster (Arutjunyan 2012) [Animal]. Pinealon has no FDA approval, no trial registered on ClinicalTrials.gov, and no published randomized human trial (all searched 2026-10-15).

Item	Status
US FDA status	Not approved; no product found on Drugs@FDA (searched 2026-10-15). No approval step announced as of that date.
Compounding (503A/503B)	Not on the 503A bulks list; not named on FDA’s Category 2 page (current as of 2026-04-22). Not on the agenda of FDA’s July 2026 compounding committee; no review scheduled.
WADA	Not named as an example in USADA guidance. S0 bans substances “not approved by any government regulatory authority” (USADA). The 2027 List (in force 2027-01-01) adds named peptide examples to S0, not pinealon; USADA warns unnamed peptides “may still be prohibited” (USADA 2027).
Strongest evidence	Human, uncontrolled (n=32), plus rat, mouse and cell studies
Human trials	0 registered on ClinicalTrials.gov (searched 2026-10-15); 3 small Russian human reports
Last checked	2026-10-15

Property	Value
Sequence	Glu-Asp-Arg (EDR), 3 amino acids
Molecular formula	C15H26N6O8
Molecular weight	418.40 g/mol
PubChem CID	10273502
Routes studied	Intraperitoneal (rats, mice); oral capsule (humans); cell culture
Class	Synthetic short peptide (“peptide bioregulator”)

What is pinealon?

Pinealon is one of a family of short synthetic peptides that Vladimir Khavinson and colleagues call “bioregulators”, a term the group uses for short peptides they propose act on gene activity in specific tissues. The family includes epitalon (Ala-Glu-Asp-Gly) and testagen; a 2011 cell study tested all three side by side and described pinealon as Glu-Asp-Arg (Fedoreyeva 2011). Despite its name, pinealon has been studied mostly in neurons and brain cortex cells rather than the pineal gland. In cultured rat pineal tissue, only epitalon raised the pinealocyte signaling marker CGRP; Glu-Asp-Arg did not (Khavinson 2011, pineal culture) [Lab]. Recent work from the same network refers to it as the “EDR peptide” and studies it as a candidate for Alzheimer’s disease (Ilina 2024).

How does pinealon work?

• Antioxidant protection: in cultured rat cerebellar neurons, neutrophils and PC12 cells, pinealon limited the build-up of reactive oxygen species in a dose-dependent way and reduced necrotic cell death (Khavinson 2011) [Lab].
• Effects beyond antioxidant action: the same study found the antioxidant effect leveled off at lower concentrations, while changes to the cell cycle and ERK 1/2 signaling continued at higher ones, which the authors read as a sign of direct action on the genome [Lab].
• DNA binding: fluorescence-labeled pinealon entered the nucleus of human HeLa cells, and in separate DNA-binding tests it appeared to bind preferentially to CAG-containing sequences (Fedoreyeva 2011) [Lab]; a physics group at Saint Petersburg State University found EDR can partly enter the major groove of DNA and contact guanine atoms (Silanteva 2019) [Lab].
• Gene regulation (hypothesis): computer modeling predicted EDR binding sites in the promoter regions of genes including CASP3, APOE, SOD2 and GAP43 (Khavinson 2021) [Lab, modeling]; a review from the group proposes it binds histones or RNA to change protein synthesis (Khavinson 2020). This has not been tested in people.
• Serotonin: Glu-Asp-Arg raised serotonin expression in aging cultures of brain cortex cells (Khavinson 2014) [Lab].

Benefits of pinealon: what the research shows

The most promising potential benefit of pinealon is protection of nerve cells under stress. In rat pups exposed to high homocysteine before birth, pinealon given to their mothers cut necrotic cerebellar neurons from 17.7% to 7.0% under oxidative challenge [Animal]. In an Alzheimer’s mouse model, EDR brought dendritic spine density back to normal [Animal], and in aging human-derived neurons it increased dendrite length by 46% [Lab].

Claim	Evidence level	Best study and result
Protects neurons from oxidative stress	Lab; Animal	Arutjunyan 2012, rats, 6 litters/group: necrotic cells 17.7% vs 7.0%; ROS 158.7 vs 108.6 units
Improves learning and memory	Animal	Arutjunyan 2012, 23 pups/group: maze search 170 s vs 137 s; Mendzheritskiĭ 2013, young and old rats
Counters Alzheimer’s-type synapse loss	Animal	Khavinson 2021, 5xFAD mice: spine density +11% (p = 0.039)
Supports aging human neurons	Lab (3 donors)	Kraskovskaya 2024: dendrite length +46% (p = 0.033); DNA damage −23% (p = 0.057, not significant)
Resistance to low oxygen	Animal	Kozina 2008: strongest effect of four peptides in hypobaric hypoxia
Slows “biological age” in people	Human, uncontrolled (n=32)	Meshchaninov 2015: improved nervous-system measures; vesugen outperformed pinealon
Work-stress resilience	Human, observational	Bashkireva 2012, truck drivers: better psychoemotional indices with pinealon plus vesugen
Sleep or melatonin	No study found	No PubMed record tests pinealon on sleep (searched 2026-10-15)

Brain protection and memory

The neuroprotection data come from several rodent models, all from the same research network. In the homocysteine study, pinealon was given to pregnant Wistar rats at 10 µg/kg, and both cell survival and maze learning improved in their offspring (Arutjunyan 2012) [Animal]. In old rats under acute hypoxia, the authors suggested pinealon brought neuroinflammatory markers (IL-6, TNF) back toward reference levels (Mendzheritskiĭ 2014) [Animal]. In a learning test, pinealon helped both young and old rats more than the comparator peptide preparation Cortexin (Mendzheritskiĭ 2013) [Animal]. Results were not uniformly positive: in old rats with blocked carotid arteries, pinealon improved survival but reduced exploratory, motivational and motor behavior (Mendzheritskiĭ 2011) [Animal].

Alzheimer’s disease models

In 5xFAD mice, which carry human Alzheimer’s mutations, two months of daily EDR restored spine density at 5 months of age to that of healthy control mice (p = 0.509 versus controls) and reduced thin spines by 10% (Khavinson 2021) [Animal]. Some measures of synaptic strengthening narrowly missed significance (p = 0.057). In induced neurons from older women, EDR increased primary dendrites by 28% (p = 0.0208); its effect on oxidative DNA damage did not reach statistical significance (Kraskovskaya 2024) [Lab].

Ageing and work capacity in people

The human reports come from Russian occupational and gerontology research and appear in the journal Advances in Gerontology. They describe improvements in “biological age” scores and stress measures, but none of their abstracts describes randomization or a placebo group, so they cannot separate the peptide’s effect from expectation or chance. They are listed in the next section.

Human studies and trials

No trial of pinealon is registered on ClinicalTrials.gov (searched 2026-10-15). The published human data are three small reports:

• Meshchaninov 2015: 32 adults aged 41–83 with several chronic diseases and organic brain syndrome received the peptides pinealon and vesugen. The authors reported improved central nervous system activity, but also pro-oxidant activity and a fall in CD34+ blood stem-cell markers; vesugen showed the clearer effect. No control group is described in the abstract.
• Nazimko 2012: locomotive crew workers took pinealon capsules for two weeks; the authors reported better biological-age and adaptation scores. The abstract gives no sample size or control group.
• Bashkireva 2012: compared 150 male truck drivers with 150 metal workers and reported that pinealon combined with vesugen improved psychoemotional indices (p < 0.001–0.05). The two peptides were given together, so pinealon’s own effect cannot be isolated.

No completed randomized, placebo-controlled trial of pinealon was found on PubMed or ClinicalTrials.gov as of 2026-10-15.

Doses used in studies

Route and amount	Species	Study
Intraperitoneal, 10 µg/kg	Pregnant rats	Arutjunyan 2012
Intraperitoneal, 400 µg/kg daily for 2 months	Mice (5xFAD)	Khavinson 2021
Cell culture, 10 µg/mL	Human induced neurons	Kraskovskaya 2024
Oral capsule, 100 µg twice a day for two weeks	Humans (workers)	Nazimko 2012

No established human dose exists outside approved labels.

Side effects and safety

No serious adverse events are described in the abstracts reviewed for this page, but the safety record is thin. A report in 32 adults given the peptides pinealon and vesugen noted pro-oxidant activity and a “significant inhibition of hemopoiesis”, meaning lower markers of blood-forming stem cells, without saying which peptide was responsible (Meshchaninov 2015) [Human, uncontrolled]. The same authors found no change in chromatin condensation, which they read as no harm at the nuclear level. In old rats, pinealon reduced motor and exploratory behavior after carotid occlusion and moderately raised activity of caspase-3, an enzyme involved in cell death (Mendzheritskiĭ 2011) [Animal].

Theoretical risks follow from the proposed mechanism. If EDR binds DNA and changes gene expression, as the Khavinson group proposes (Khavinson 2020), its long-term effects on gene activity are unstudied; no long-term toxicology or cancer study was found on PubMed (searched 2026-10-15).

Because no pinealon product is FDA-approved (Drugs@FDA, searched 2026-10-15), no product sold in the US has had its identity, purity, sterility or strength reviewed by FDA; our page on what the “research use only” label means explains the legal position of such products. With no label, no regulator has defined who should not use it, and there are no published data in pregnancy, breastfeeding, children or people taking other medicines.

Anyone who suspects a side effect from pinealon or any other drug or product can report it to the FDA through MedWatch.

Legal and regulatory status

Jurisdiction	Status (checked 2026-10-15)
US FDA	Not approved; no product on Drugs@FDA
503A bulks list	Not listed (21 CFR 216.23)
FDA categories 1–3	Not named (Category 2 page, 2026-04-22)
FDA advisory committee	Not on the July 2026 agenda
WADA 2026 List	Not named as an example; S0 covers non-approved substances (USADA)
WADA 2027 List	Not named; unnamed peptides “may still be prohibited” (USADA)
Clinical trials	None registered (ClinicalTrials.gov)

FDA’s 503A page says the agency “does not intend to place bulk drug substances nominated on or after January 7, 2025, into these categories” (FDA, 503A bulks), so a new nomination of pinealon would not receive an interim category. Our explainer on what FDA’s Category 1 and Category 2 compounding lists mean covers how that system works. Unlike its sibling epitalon, which was reviewed for insomnia, pinealon was not on the agenda when FDA’s Pharmacy Compounding Advisory Committee met on 2026-07-23/24 (FDA meeting page). For athletes, the 2027 List keeps the S0 class; our page on which peptides WADA prohibits in 2027 lists the named examples. We found no UK, EU or Australian regulator page naming pinealon, so no status is given for those jurisdictions.

Related peptides

• Epitalon (Ala-Glu-Asp-Gly): the best-known Khavinson bioregulator, a separate four-amino-acid peptide studied for the pineal gland and ageing.
• Semax: a Russian-developed neuropeptide studied for stroke and cognition.
• DSIP (delta sleep-inducing peptide): the peptide most often searched alongside pinealon for sleep.
• GHK-Cu (copper tripeptide-1): another three-amino-acid peptide studied in ageing, mainly of skin.